Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 157

Results For "NAL"

6624 News Found

Dr. Lal PathLabs pioneers AI integration in cancer diagnosis in India
Digitisation | August 21, 2025

Dr. Lal PathLabs pioneers AI integration in cancer diagnosis in India

The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases


HGM acquires Aideo Technologies for Rs. 14 crore to strengthen AI-powered healthcare services platform
Digitisation | August 21, 2025

HGM acquires Aideo Technologies for Rs. 14 crore to strengthen AI-powered healthcare services platform

This acquisition expands HGM's healthcare platform capabilities in revenue cycle management


SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction
Healthcare | August 21, 2025

SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction

The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries


Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders
News | August 20, 2025

Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise


Glenmark Pharmaceuticals USA to launch Micafungin for injection USP, 50 mg/vial and 100 mg/vial
News | August 19, 2025

Glenmark Pharmaceuticals USA to launch Micafungin for injection USP, 50 mg/vial and 100 mg/vial

According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million


Novo Nordisk's Wegovy approved in the US for the treatment of MASH
News | August 19, 2025

Novo Nordisk's Wegovy approved in the US for the treatment of MASH

The accelerated approval is supported by results from part 1 of the ESSENCE trial


Sarepta advances siRNA collaboration and sale of arrowhead equity investment
News | August 19, 2025

Sarepta advances siRNA collaboration and sale of arrowhead equity investment

Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation


BioAge Labs doses first patient in BGE-102 phase 1 trial
Biotech | August 19, 2025

BioAge Labs doses first patient in BGE-102 phase 1 trial

The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants